You and your family are our top priority. At Fred Hutch Cancer Center, we offer comprehensive and compassionate care — personalized to you. You'll have access to the latest treatment options, clinical ...
Results showed tarlatamab significantly reduced the risk of death by 40% vs standard of care treatment (HR, 0.60 [95% CI, 0.47-0.77]; P .001). The Food and Drug Administration (FDA) has granted ...
Leah Phillips, a Kentucky mom of three, said she was initially told her symptoms were due to a cold, allergies or anxiety ...
This antibody-drug conjugate targets a specific protein associated with poor prognosis in patients whose disease progressed after platinum-based chemotherapy.
Dr. Charles M. Rudin discussed recent treatment advancements for patients with small cell lung cancer. During the CURE Educated Patient® Lung Cancer Summit, held in tandem with the 2025 PER® New York ...
If approved, ifinatamab deruxtecan would be a first-in-class B7-H3 directed DXd antibody drug conjugate for these patients ...
Clinical trial collaboration and supply agreement between Boehringer and BioNTech to conduct a Phase Ib/II clinical trial to explore ...
Results of a new study conclude that a pathology tool powered by artificial intelligence can predict whether a patient with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results